Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Dementia lithium

Mood Stabilizers. Lithium (Eskalith, Lithobid), valproic acid (Depakene), sodium valproate (Depakote), and carbamazepine (Tegretol) are most often used by psychiatrists to treat the bipolar disorders. These so-called mood stabilizers are also used to treat impulsivity and agitation in a variety of psychiatric disorders including dementia, certain personality disorders, and the disruptive behavior disorders of childhood. [Pg.248]

Mood Stabiiizers. First lithium and more recently valproic acid (Depakote, Depakene), carbamazepine (Tegretol), and gabapentin (Neurontin) have been used to treat agitated dementia patients. [Pg.302]

Therapeutic Potential of Inositol Treatment in Depression, Panic, Dementia, and Lithium Side Effects... [Pg.159]

Bowden CL, Brugger AM, Swann AC, et al Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA 271 918-924, 1994b Bowen DM, Davison AN Biochemical studies of nerve cells and energy metabolism in Alzheimer s disease. Br Med Bull 42 75-80, 1986 Bowen DM, Smith CB, White P Accelerated ageing or selective neuronal loss as an important cause of dementia Lancet 1 11-14, 1979 Bowen DM, Smith CB, White P, et al Biochemical assessment of serotonergic and cholinergic dysfunction and cerebral atrophy in Alzheimer s disease. J Neuro-chem 41 266-272, 1983... [Pg.601]

Cummings JL, Miller B, Hill MA, et al Neuropsychiatric aspects of multi-infarct dementia and dementia of the Alzheimer type. Arch Neurol 44 389-393, 1987 Cundall RL, Brooks PW, Murray LG A controlled evaluation of lithium prophylaxis in affective disorders. Psychol Med 2 308-311, 1972 Cutler NR, Haxy J, Kay AD, et al Evaluation of zimeldine in Alzheimer s disease cognitive and biochemical measures. Arch Neurol 42 744-748, 1985 Czyrak A The effect of chronic nifedipine and ECS in the forced swimming test in rats. PolJ Pharmacol 45 191-195, 1993... [Pg.619]

Freeman TW, Clothier JL, Pazzaglia P, et al A double-blind comparison of valproate and lithium in the treatment of acute mania. Am J Psychiatry 149 108-111,1992 Frenchman IB, Prince T Clinical experience with risperidone, haloperidol, and thioridazine for dementia-associated behavioral disturbances. Int Psychogeriatr 9 431-435, 1997... [Pg.639]

Hong J-S, Tilson HA, Yoshikawa K Effects of lithium and haloperidol administration on the rat brain levels of Substance P. J Pharmacol Exp Ther 224 590-597, 1983 Honig A, Bartlett JR, Bouras N, et al Amino acid levels in depression a preliminary investigation. J Psychiatr Res 22 159-164, 1989 Honjo H, Ogino Y, Natitoh K, et al In vivo effects by estrone sulphate on the central nervous system on senile dementia [Alzheimer s type). Journal of Steroid Biochemistry 34 521-525, 1989... [Pg.661]

Mellow AM, Solano-Lopez C, Davis S Sodium valproate in the treatment of behavioral disturbance in dementia. J Geriatr Psychiatry Neurol 6 28-32, 1993 Meltzer HL Mode of action of hthium in affective disorders an influence on intracellular calcium functions. Pharmacol Toxicol 66 84-99, 1990 Meltzer HL, Kassir S, Dunner DL, et al Repression of a lithium pump as a consequence of hthium ingestion by manic-depressive subjects. Psychopharmacology 54 113-118, 1982... [Pg.696]

Mufson EJ, Cochran E, Benzing W, et al Galaninergic innervation of the cholinergic vertical limb of the diagonal band (Ch2) and bed nucleus of the stria terminahs in aging, Alzheimer s disease and Down s syndrome. Dementia 4 237-250, 1993 Muhlbauer HD The influence of fenfluramine stimulation on prolactin plasma levels in lithium long-term-treated manic-depressive patients and healthy subjects. Pharmacopsychiatry 17 191-193, 1984... [Pg.704]

Reifler BV, Teri L, Raskind M, et al Double-bhnd trial of imipramine in Alzheimer s disease patients with and without depression. Am J Psychiatry 146 45-49, 1989 Reisberg B, Ferris SH, DeLean MJ, et al The Global Deterioration Scale for Assessment of Primary Degenerative Dementia. Am J Psychiatry 139 1136-1139, 1982 Reisine T, Zatz M Interactions between lithium, calcium, diacylglycerides and phorbol esters in the regulation of ACTEl release from AtT-20 cells. J Neurochem 49 884-889, 1987... [Pg.730]

Whitehouse PJ, Price DL, Clark AW, et al Alzheimer disease evidence for selective loss of cholinergic neurons in the nucleus basahs. Ann Neurol 10 122-126, 1981 Whitehouse PJ, Price DL, Struble RG, et al Alzheimer s disease and senile dementia—loss of neurons in the basal forebrain. Science 215 1237-1239, 1982 Whitehouse PJ, Hedreen JC, White CL, et al Basal forebrain neurons in dementia of Parkinson s disease. Ann Neurol 13 243-248, 1983 Whitehouse P, Martino A, Antuono P, et al Nicotinic acetylcholine binding sites in Alzheimer s disease. Brain Res 371 146-151, 1986 Whitehouse PJ, Martino AM, Marcus KA, et al Reductions in acetylcholine and nicotine binding in several degenerative diseases. Arch Neurol 45 722-724, 1988 Whitton PS, Sama GS, O Connell MT The effect of the novel antidepressant tianeptine on the concentration of 5-hydroxytryptamine in rat hippocampal diasylates in vivo. Neuropharmacology 39 1-4, 1991 Whitworth P, Kendall DA Lithium selectively inhibits muscarinic receptor-stimulated inositol tetrakisphosphate accumulation in mouse cerebral cortex slices. J Neurochem 51 258-265, 1988... [Pg.768]

In regard to neuroleptics, we found that pioneers in their use were most straightforward about its brain-disabling effects. We find the same phenomenon with lithium. Cade (1949) indicated that lithium, when used for other medicinal purposes, produced actual mental depression in a variety of patients, not just those suffering from mania or manic depression. The drug enforced a so-called quieting effect on persons he considered schizophrenic (dementia praecox, in his nosology) ... [Pg.202]

Comments on the generally favorable effects of lithium on immune function have been summarized (46). The antiviral and neuroprotective properties of lithium were mentioned in a review of the immune system and bipolar disorder (47). The potential benefit of lithium in treating AIDS and AIDS-related dementia, owing in part to its cytokine-regulating and neuroprotective effects, has been reviewed (48). Genital Herpes simplex infection has responded to lithium (49). [Pg.127]

A 66-year-old man presented comatose with an EEG suggestive of Creutzfeldt-Jakob encephalopathy after an 11-month history of progressive dementia and parkinsonism (188). Lithium (serum concentration 1.3 mmol/1), which he had been taking for 13 years,... [Pg.135]

Clinically, lithium may protect patients against dementia, although it has been reported that patients who take lithium are actually at a higher risk of developing... [Pg.137]

Dunn N, Holmes C, Mullee M. Does lithium therapy protect against the onset of dementia Alzheimer Dis Assoc Disord 2005 19(l) 20-2. [Pg.171]

Harvey BH, Meyer CL, GaUichio VS, Manji HK. Lithium salts in AIDS and AIDS-related dementia. Psychopharmacol Bull 2002 36(l) 5-26. [Pg.2103]

Dementia Lithium has neuroprotective properties in vivo. In human endothelial cell and rat cortical astrocyte cultures, lithium 0.2 mmol/l increased phosphorylation of GSK-3P (inactivation of GSK-3f) and promoted secretion of vascular endothelial growth factor (VEGF) [2( ]. The effect on GSK-3P may be more general, since lithium also reduced GSK-3 concentrations in primary cultures of rat cortical and hippocampal cells [21 ] and in neural precursor cells [22 ]. This effect on GSK-3j3 expression and activity is probably related to the observation that lithium treatment of primary culture cortical cells reduces both tau protein concentrations and tau phosphorylation (tau is phosphorylated by GSK-3 ) [23 ]. Similarly, in PCI2 cells, lithium 1.2 mmol/l reduced morphine-induced apoptosis by down-regulating the BAX, which is pro-... [Pg.42]

At the organ level, lithium has been associated with an increase in cortical grey matter as examined using structural magnetic resonance imaging (MRI) [25 ] and an increase in N-acetyl-aspartate, a derivative of aspartic acid, which is a marker of neuronal health, measured by magnetic resonance spectroscopy [26 j. These neuroprotective characteristics of lithium may reduce the risk of dementia. [Pg.42]

In an observational cohort study using national medical databases in Denmark, patients who had received a prescription for lithium at least once (n = 16 238) had a higher rate of subsequent dementia than those who had never used lithium (n = 1 487 1 77) (RR = 1.47 95% Cl = 1.22,... [Pg.42]

For all these reasons, it is not surprising that lithium has independently been proposed in Alzheimer s disease as a potential agent for prevention [28 ] and treatment [29 ]. The effects of lithium have been studied for up to 1 year in 22 patients with Alzheimer s disease, of whom 14 stopped the study early, in three cases because of adverse effects [30 ]. The Mini-Mental State Fxam (MMSF) score did not change in those who took lithium compared with the controls. In a 10-week, randomized, placebo-controlled study of lithium in 71 subjects with mild dementia (MMSF 21-26 38 placebo, 33 lithium) there was no change in cognition, mood, GSK-3 activity in lymphocytes, or phosphorylated tau concentrations in the cerebrospinal fluid [31 ]. [Pg.42]

A 42-year-old woman developed dementia in the setting of atrophy and multiple diffuse areas of brain calcihcation when she took lithium for antidepressant drug-associated mania [50 ]. She became semi-comatose, with dysarthria and right-sided dystonia. Her serum lithium concentration was only 0.57 mmol/1, but her neurological signs resolved when lithium was discontinued. [Pg.44]

Kessing LV, Spndergard L, Forman JL, Andersen PK. Lithium treatment and risk of dementia. Arch Gen Psychiatry 2008 65 (11) 1331-5. [Pg.50]


See other pages where Dementia lithium is mentioned: [Pg.405]    [Pg.481]    [Pg.88]    [Pg.596]    [Pg.606]    [Pg.608]    [Pg.686]    [Pg.205]    [Pg.138]    [Pg.42]   
See also in sourсe #XX -- [ Pg.41 ]




SEARCH



© 2024 chempedia.info